Estimates of comparative efficacy of ASAQ and AL for treatment of the first episode of malaria: Per protocol (PP) population.

Values are for all subjects completing the first episode of the study according to protocol (PP population).
aASAQ was considered non-inferior to AL if the lower limit of the one-sided 95% confidence interval was>−5%.
bP-value was determined by Fisher's exact test.
cP-value was determined by Wilcoxon's signed-rank test.
dP-value was determined by Chi-squared test.
Estimates of comparative efficacy of ASAQ and AL for treatment of the first episode of malaria: Per protocol (PP) population.

本研究数据均来自所有按照试验方案完成研究首阶段的受试者，即符合方案人群（Per Protocol population，PP人群）。
a 若单侧95%置信区间的下限大于−5%，则认为青蒿琥酯-阿莫地喹复方（Artesunate-Amodiaquine，ASAQ）非劣于蒿甲醚-本芴醇复方（Artemether-Lumefantrine，AL）。
b P值采用Fisher精确检验计算得出。
c P值采用Wilcoxon符号秩检验计算得出。
d P值采用卡方（Chi-squared）检验计算得出。
青蒿琥酯-阿莫地喹复方与蒿甲醚-本芴醇复方治疗首次疟疾发作的疗效对比评估：符合方案人群（Per Protocol population，PP人群）。